Some days she only managed protein shakes and Greek yogurt
Accordingly, and in line with currently ongoing trials in HFpEF (ClinicalTrials.gov IDs NCT04916470 and NCT04788511), it may be relevant to consider obesity-related HFpEF as a specific (sub)phenotype, whether coexisting with type 2 diabetes or not
[4] [5] Such development typically takes many years and must meet rigorous regulatory standards set by the MHRA and European Medicines Agency (EMA) before any product could be approved for patient use
What is unknown about GLP-1 drug use is as important as what is known
The ability to address multiple health concerns with a single medication could simplify treatment regimens and improve patient outcomes
The lawsuits involve claims that Ozempic and other GLP-1 receptor agonist drugs, including Wegovy and Mounjaro, caused serious gastrointestinal injuries such as gastroparesis, or stomach paralysis